Citations

Clear

6728 citation(s) found for "Li, Mark".

Health Care Utilization and Costs Associated With Blue-Light vs White-Light Cystoscopy: A Real-World Bladder Cancer Population
Tyson, Mark D, Choudry, Mouneeb M, McKee, Chad, Kalaria, Shiv, James, Cerise, Engel-Nitz, Nicole, Johnson, Mary G. , Choudry, Mouneeb M , Engel-Nitz, Nicole M , Tyson, Mark D. , McKee, Chad M., Barnes, Timothy L.

Mayo Clinic

JU Open Plus | August 11, 2026 | Volume: 4 | Issue: 8 | Pages: No page available

10.1097/ju9.0000000000000491 | PMID 42565160 Get It

Purpose: Compared with white-light cystoscopy (WLC), blue-light cystoscopy (BLC) enhances detection of non–muscle-invasive bladder cancer (NMIBC), especially carcinoma in situ (CIS). However, its effects on health care resource utilization and cost burden have not been fully elucidated. This study assessed the economic implications of BLC vs WLC. Materials and Methods: We conducted a retrospective cohort analysis with claims data from the Optum Research Database between June 2011 and May 2023. Patients who underwent BLC or WLC were identified, and white-light patients were matched 6:1 to blue-light patients by index year and time between bladder cancer diagnosis and cystoscopy. Inverse probability of treatment weighting was used to adjust for baseline differences. Health care resource utilization and total and bladder cancer–specific costs were calculated on a per-patient-per-month basis. Results: The final cohort included 794 blue-light and 4764 white-light patients. Before weighting, claims coded for CIS were more frequent in blue-light patients (19.6% vs 8.8%; P < .001). Blue-light patients underwent more upper-tract imaging (71.8% vs 57.8%; P < .001), BCG (24.2% vs 15.8%; P < .001), and biomarker testing (65.0% vs 34.9%; P < .001). After weighting, blue-light patients had a higher mean number of bladder cancer–related ambulatory visits per month (1.3 vs 1.0; P = .004). However, neither all-cause health care resource utilization (3.47 vs 3.21; P = .11) nor total cost ($2987.93 vs $2886.16, per patient per month, P = .65) differed significantly between cohorts. Conclusions: BLC is associated with greater health care resource utilization for NMIBC without significantly elevating health care costs, suggesting that enhanced diagnostic strategies can be implemented without added financial burden in real-world practice.
Combined FAK and MEK inhibition suppresses chromosome 8 gain malignant peripheral nerve sheath tumors
Wang, Guangfeng , Wang, Jiawan , Zhang, Xiaochun, Yang, Liuzhan , Oztosun, Gorkem, Sears, James J., Xiao, Ke , Garana, Belinda B., Zoberi, Mark I., Bektas, Aaron U., Coma, Silvia, Pachter, Jonathan A. , Gosline, Sara JC, Pratilas, Christine A. , Szymanski, Jeffrey J. , Borcherding, Dana C. , Zhang, Xiaochun, Oztosun, Gorkem , Sears, James J. , Garana, Belinda B. , Rathore, Richa , Coma, Silvia, Gosline, Sara J.C. , Hirbe, Angela C.

Mayo Clinic

Journal of Clinical Investigation | August 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1172/jci201331 | PMID 42579369 Get It

Aneuploidy is a hallmark of cancer often associated with inferior prognosis. Copy number gains of chromosome 8 (chr8) are recurrent in multiple cancers, including breast, prostate, colorectal cancers, and sarcomas such as malignant peripheral nerve sheath tumors (MPNSTs). MPNSTs are aggressive, hard-to-treat sarcomas frequently linked to the Neurofibromatosis type 1 (NF1) cancer predisposition syndrome. To investigate the role of chr8 gain in MPNST pathogenesis, we performed a CRISPR knockout screen and identified 58 essential genes on chr8, including PTK2, which encodes focal adhesion kinase (FAK). We evaluated FAK as a therapeutic target and tested small-molecule FAK inhibitors (FAKi) alone or combined with RAF/MEK inhibitors (RAF/MEKi), a class of agents relevant to NF1-deficient tumors with ERK pathway hyperactivation. Both pharmacological and genetic inhibition of FAK reduced MPNST cell proliferation in vitro and tumor growth in vivo. Combined FAKi and RAF/MEKi treatment further suppressed phosphorylation of FAK, STAT3, and AKT while increasing cleaved caspase-3 and PARP-1, indicating enhanced apoptosis. In MPNST patient-derived xenograft (PDX) models, combination therapy significantly reduced tumor growth, showing superior efficacy, particularly in chr8 gain MPNST-PDX. These results support FAK/RAF/MEK co-targeting as a promising therapeutic strategy for chr8 gain MPNST and related tumors.
Prescription Trends for Bipolar Disorder With and Without Comorbid Substance Use and Anxiety Disorders: A Global Bipolar Cohort Collaborative Study
Yocum, Anastasia K. , Aouizerate, Bruno, Aubin, V. , Bellivier, Frank , Belzeaux, Raoul , Berk, Michael , Biernacka, Joanna M. , Budde, Monika , Burdick, Katherine E. , Coombes, Brandon J., Diaz‐Byrd, Claudia , Dubertret, Caroline, Fico, Giovanna, Godin, Ophélia , Gordon‐Smith, Katherine, Januel, Dominique, Lefrère, Antoine , Llorca, Pierre‐Michel, Mwangi, Benson, Olie, Emilie, Overs, Bronwyn J. , Petite, Joanne, Polosan, Mircea , Rey, Romain, Roberts, Gloria, Schwan, Raymund, Serretti, Alessandro , Soares, Jair C., Stross, Tatjana , Walter, Michel, Williams, Lana J., Wu, Mon‐Ju, Young, Allan H. , Zunta‐Soares, Giovana B., Frye, Mark A. , McInnis, Melvin G., Roberts, Gloria , Alda, Martin , Bellivier, F , Belzeaux, Raoul , Berk, Michael , Biernacka, Joanna , Budde, Monika , Burdick, K E , Chang, Yun-Hsuan , Courtet, Philippe , Dalkner, Nina , Etain, B , Fullerton, Janice M , Godin, Ophelia , Haffen, Emmanuel , Keramatian, Kamyar , Leboyer, Marion , Majd, Marzieh , Mitchell, Philip B , Polosan, Mircea , Roux, Paul , Samalin, Ludovic , Serretti, Alessandro , Sperry, Sarah , Strawbridge, Rebecca , Stross, Tatjana , Vieta, E , Williams, Lana J , Yatham, Lakshmi N , Young, Allan H , Yrondi, Antoine , Frye, Mark , Singh, Balwinder , Alda, Martin , Aouizerate, Bruno , Coombes, Brandon J. , Dubertret, Caroline , Étain, Bruno , Fico, Giovanna , Fullerton, Janice M. , Gordon‐Smith, Katherine , Januel, Dominique , Keramatian, Kamyar , Leboyer, Marion , Llorca, Pierre‐Michel , Mwangi, Benson , Olié, Émilie , Rey, Romain , Samalin, Ludovic , Schwan, Raymund , Soares, Jair C. , Sperry, Sarah H. , Strawbridge, Rebecca , Vieta, Eduard , Walter, Michel , Wu, Mon‐Ju , Yatham, Lakshmi N. , Zunta‐Soares, Giovana B. , McInnis, Melvin G. , Singh, Balwinder

Mayo Clinic

Bipolar Disorders | August 11, 2026 | Volume: 28 | Issue: 6 | Pages: No page available

10.1111/bdi.70167 | PMID 42578538 Get It

ABSTRACT Objectives To investigate pharmacological treatment patterns in individuals with bipolar disorder (BD) with and without comorbid substance use disorder (SUD) and anxiety disorder (AX), we leveraged the Global Bipolar Cohort to analyze cross‐regional practices across North America, Europe, and the Pacific. Methods Fourteen cohorts contributed aggregate data on pharmacotherapy, demographics, diagnostic subtypes, and comorbidities. Proportional meta‐analyses using generalized linear mixed models were conducted to examine prescription trends and identify clinical differences. Results The sample ( N = 11,521) was 60% female and 84% Caucasian. Participants were categorized into four mutually exclusive groups based on comorbidity status: those with comorbid AX only, comorbid SUD only, both AX and SUD, or neither. The AX+SUD subgroup showed higher rates of attention‐deficit/hyperactivity disorder (ADHD), post‐traumatic stress disorder (PTSD), rapid cycling, obesity, and unemployment, reflecting a more severe clinical profile. Regional variations were notable: North American cohorts reported higher prevalence of AX and SUD than European and Pacific cohorts. Antidepressants use for AX were more common in Europe and the Pacific, while North American prescribing patterns were more variable. Benzodiazepine use was high among individuals with SUD across all regions. Lithium and first‐generation antipsychotic prescriptions varied, with higher rates observed in Europe. Conclusions Findings underscore the heterogeneity of BD and the influence of comorbid AX and SUD on illness burden and treatment. Regional prescribing variations underscore the need for context‐specific guidelines. Gaps in data on medication‐assisted treatment for SUD point to areas for future research. These insights can support more individualized and effective care for complex BD presentations.
Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project
Miola, Alessandro , Croatto, Giovanni , Carvalho, Andre F, Berk, Michael, Nikolitch, Katerina , Saraf, Gayatri , Yatham, Lakshmi N, Frye, Mark A, Singh, Balwinder, Krinitski, Damir , Højlund, Mikkel , Serretti, Alessandro , Gomes, Fabiano A, Hansen, Anne Sofie , Nielsen, Rene Ernst, Manchia, Mirko, Vazquez, Gustavo, Siafis, Spyridon, Leucht, Stefan, Yıldız, Ayşegül, Delorme, Richard, Schaffer, Ayal , Stubbs, Brendon , Rubaiyat, Ruby , Vieta, Eduard, Correll, Christoph U, Moher, David, Cortese, Samuele, Fiedorowicz, Jess G, Solmi, Marco , Berk, Michael , Solmi, Marco , Berk, Michael , Serretti, Alessandro , Prisco, Michele De , Oliva, Vincenzo , Fornaro, Michele , Dragioti, Elena , Yatham, Lakshmi N. , Keramatian, Kamyar , Shorr, Risa , Frye, Mark A. , Singh, Balwinder , Fanelli, Giuseppe , Gomes, Fabiano A., Nielsen, René Ernst , Fusar‐Poli, Paolo , Paribello, Pasquale , Manchia, Mirko , Bahji, Anees , Vázquez, Gustavo Héctor , Siafis, Spyridon , Leucht, Stefan , Delorme, Richard , Vieta, Eduard , Correll, Christoph Ulrich , Moher, David , Cortese, Samuele , Fiedorowicz, Jess G. , Raduà, Joaquim , Gosling, Corentin J.

Mayo Clinic

BMJ | August 11, 2026 | Volume: 394 | Issue: No issue available | Pages: e100216

10.1136/bmj-2026-100216 | PMID 42580772 Get It

Abstract Objectives To systematically evaluate the certainty of evidence for treatment strategies across age groups and mood phases in bipolar disorder, and develop an open access web platform to facilitate shared decision making. Design Living umbrella review, evaluation, analysis, and communication hub (U-REACH) project. Data sources PubMed, PsycInfo, and Cochrane library databases, from inception to 19 November 2024. Eligibility criteria for selecting studies Systematic reviews with network or pairwise meta-analyses of randomised controlled trials of pharmacological, nutraceutical, psychosocial, brain stimulation, or circadian rhythm based treatments, administered as monotherapy (without concurrent interventions), augmentation treatment (interventions added to an ongoing treatment regimen), or combination treatment (simultaneous initiation of two different interventions), examining any age group, bipolar disorder phase (ie, acute bipolar depression, mania or mixed episodes, or maintenance), treatment, control, or outcome. Results 77 studies met the inclusion criteria (21 network meta-analyses and 56 pairwise meta-analyses), including 116 unique pharmacological (n=74), brain stimulation (n=18), nutraceutical (n=13), psychosocial (n=8), and circadian rhythm based (n=3) treatments as monotherapy, augmentation, or combination therapy, along with five control interventions. These studies covered 133 unique outcomes (45 efficacy outcomes and 88 safety outcomes) resulting in 2510 meta-analyses with Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) ratings of the certainty of the evidence as high (n=236), moderate (n=827), low (n=986), and very low (n=461). A communication hub, the Evidence Based Interventions for Bipolar Disorder (EBI-BD) platform, was developed and the full results are freely available ( https://ebibd-database.org ), including the preference based tool (12 interventions and 17 safety outcomes). Interventions effective across outcomes varied by phases. For bipolar depression, effective interventions in adults were cariprazine, divalproex or valproate, fluoxetine, ketamine (augmentation), lamotrigine, lumateperone, lurasidone, olanzapine, olanzapine with fluoxetine, and quetiapine, whereas effective interventions in children and adolescents were lurasidone and olanzapine with fluoxetine. For mania episodes, effective interventions in adults were aripiprazole, asenapine, carbamazepine, cariprazine, divalproex or valproate, haloperidol, lithium, olanzapine, paliperidone, quetiapine (also augmentation), risperidone (also as augmentation), tamoxifen, and ziprasidone, whereas effective interventions in children and adolescents were aripiprazole, asenapine, olanzapine, quetiapine, and risperidone. For maintenance, interventions effective across outcomes in adults were aripiprazole (also the long acting injectable formulation), asenapine, divalproex or valproate, lithium, olanzapine, group psychoeducation (augmentation), quetiapine, and risperidone long acting injectable formulation. Interventions effective across phases were aripiprazole (also as augmentation and as a long acting injectable formulation), asenapine, cariprazine, cognitive behavioural therapy (augmentation), divalproex or valproate, lamotrigine, lithium, olanzapine (also as augmentation), paliperidone, quetiapine (also as augmentation), and risperidone (also as augmentation and the long acting injectable formulation) (adults). Treatment effects by neuroscience based nomenclature classes are also reported. Conclusions The EBI-BD tool can help clinicians make evidence based, personalised treatment decisions for bipolar disorder. This resource can inform clinical guidelines and provides a foundation for continuously improving bipolar disorder care as new evidence emerges. Trial registration Open Science Framework https://osf.io/pjmvn/ Readers’ note This is a living systematic review and may be updated in the next two years if additional evidence emerges.
Beyond BMI: an interpretable integrated body composition index from low-dose chest CT for all-cause mortality risk stratification: a multicentre study
Patel, Krishna K., Miller, Robert J.H, Marcinkiewicz, Anna M , Kamagate, Assiata, Shanbhag, Aakash, Hijazi, Waseem , Lemley, Mark, Zhou, Jianhang, Liang, Joanna X. , Ramirez, Giselle, Mostafavi, Shiva , Urs, Meghana, Travin, Mark, Alexanderson, Erick, Caraval-Juarez, Isabel, Ruddy, Terrence D., Einstein, Andrew J., Feher, Attila, Le, Viet T, Mason, Steve, Calsavara, Vinicius F., Chareonthaitawee, Panithaya, Wopperer, Samuel, Wang, Lixia, Li, Debiao, Lopez-Ramirez, Felipe, Berman, Daniel S., Kwieciński, Jacek , Dey, Damini, Carli, Marcelo Di, Li, Debiao , Miller, Robert J.H. , Miller, Robert J H , Li, Debiao , Yi, Jirong , Lemley, Mark , Zhou, Jianhang , Urs, Meghana , Spielvogel, Clemens P. , Slipczuk, Leandro , Travin, Mark I. , Alexanderson, Erick , Packard, René R. Sevag , Al‐Mallah, Mouaz H. , Ruddy, Terrence D , Einstein, Andrew Jeffrey , Feher, Attila , Miller, Edward J. , Acampa, Wanda , Knight, Stacey , Le, Viet T. , Mason, Steve, Calsavara, Vinicius F , Chareonthaitawee, Panithaya , Kwan, Alan C. , Li, Debiao, Fishman, Elliot K. , Lopez-Ramirez, Felipe, Berman, Daniel S. , Dey, Damini , Carli, Marcelo F. Di , Slomka, Piotr J , Zhou, Jianhang , Slipczuk, Leandro , Packard, Rene R S , Al-Mallah, Mouaz H , Miller, Edward J , Fishman, Elliot K.

Mayo Clinic

No container title available | August 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.05.26359437 | PMID 42845593 Get It

Summary Background Body composition is recognized as a major determinant of health outcomes, but its multidimensional nature makes clinical adoption challenging. We sought to develop and validate a body composition index (BCI) for all-cause mortality risk assessment, integrating variables of six body composition tissues. Methods We analyzed 28509 consecutive patients undergoing myocardial perfusion imaging with routine low-dose chest CT attenuation correction (CTAC) scans acquired during myocardial perfusion imaging (MPI) at 12 centers across four countries. An artificial intelligence-based BCI was developed in a cohort of 15037 patients’ CTACs by integrating the CT-derived metrics of bone, skeletal muscle, and four adipose tissue compartments, coronary artery calcium score, and basic demographic variables (age, sex, BMI). The performance of BCI for mortality prediction was validated in an internal cohort of 6444 patients and an external cohort of 7028 patients by prognosis, calibration, net benefit, and explainability. Model-based simulation of tissue metrics modification was performed to evaluate estimated mortality risk reduction. Findings During a median of 3.5 (IQR [1.9, 5.1]) years, 4697 (16%) patients died. In the external testing cohort, the BCI demonstrated excellent discrimination for mortality (area under receiver operating characteristic curve 0.78 (95% CI [0.76, 0.79]) and Harrell’s concordance index 0.75 [0.73, 0.76]), calibration, and net benefit overall and across pre-specified subgroups stratified by patient characteristics and imaging protocols. Visceral adipose tissue attenuation was the most influential body composition measure, followed by skeletal muscle volume. Simulated improvement in body composition was associated with significant mortality risk reduction. Interpretation An index combining six body composition measures obtained opportunistically from routine chest CT provides robust mortality risk stratification. By converting complex body composition information into a single interpretable score, the BCI can facilitate clinical implementation of opportunistic CT biomarkers and guide individualized preventive strategies. Funding National Institute of Health Research in context Evidence before this study We searched PubMed and Google Scholar on July 7, 2026 for English language studies using the terms (“mortality prediction” OR “death prediction”) AND (“integrated body composition analysis” OR “body composition metrics integration”) AND (“predictive model” OR “model development”), and identified 41 publications describing predictive models incorporating body composition metrics. Recent advances in artificial intelligence (AI) have enabled increasingly granular quantification of body composition from CT, with multiple tissues and tissue-specific metrics showing independent prognostic value for all-cause mortality (ACM) prediction. However, reported associations of body composition metrics with mortality risk were highly inconsistent or even contradictory across studies. This heterogeneity likely reflected the differences in study design or the inherent complexity of body composition analysis, such as the interaction among variables derived from multiple tissues. Thus, it is difficult to interpret body composition results reliably in clinical practice. We hypothesized that integrating multiple body composition metrics could achieve comprehensive and reliable prediction of mortality across patient populations. Added value of this study In this large international, multicenter longitudinal cohort study of 28509 consecutive patients with suspected or known coronary artery disease (CAD) undergoing myocardial perfusion imaging across 12 sites in four countries, we developed and externally validated an artificial intelligence-based body composition index (BCI) for all-cause mortality prediction. The BCI integrated chest CT-derived metrics of six body composition tissue compartments – bone, skeletal muscle (SM), subcutaneous adipose tissue (SAT), intramuscular adipose tissue (IMAT), visceral adipose tissue (VAT), and epicardial adipose tissue (EAT), together with demographics (age, sex, BMI) and CT-derived coronary artery calcium (CAC) score, all derived automatically from routine low-dose attenuation correction CT scans without additional imaging or laboratory tests. In an external validation cohort of 7028 patients, the BCI achieved robust discrimination for mortality prediction, substantially outperforming a baseline model using demographics and calcium score alone, and exceeded the discriminative performance of prior body composition models. Performance was consistent across subgroups defined by sex, age, body mass index, cardiometabolic risk factors, imaging modality, and acquisition protocol, supporting generalizability across clinical settings. The BCI demonstrated excellent calibration and net clinical benefit. Explainability analysis identified visceral adipose tissue attenuation and skeletal muscle volume as the dominant contributors to mortality risk, offering tissue-specific therapeutic targets that complement generic weight-based metrics. Model-based simulations suggested that improvements in these specific compartments could reduce estimated mortality risk more effectively than equivalent changes in BMI alone, pointing toward precision therapeutic targets beyond weight reduction. Our study improved over previous literatures on body composition-based predictive models in one or more of the following ways: (1) we considered six types of body composition tissues while existing studies considered only three or less tissues, thus significantly higher granularity and improved ability to capture refined tissue interactions; (2) our model was rigorously validated in external sites, showing cross-site generalizability while most previous work lacked external validation; (3) our model achieved significant prediction performance improvement over previous body composition predictive models, offering better clinical outcomes prediction and facilitating the suitability for widespread clinical adoption; (4) our study was conducted with a large multi-center cohort across multiple countries, achieving statistical power and demonstrating reliability towards patients characteristics and imaging acquisition protocols while previous studies involved small single-center cohorts; (5) our model required only CT scans and basic demographics which were widely available in clinical routine while the existing models required dedicated laboratory tests or specialized imaging modalities, enhancing the applicability in routine clinical practice. Implications of all the available evidence BCI offers an explainable and clinically deployable tool for improved prediction of mortality risk from existing chest CT scans. Its use could inform updates to existing risk models, guide precision preventive strategies, and support development of therapeutics targeting specific body composition phenotypes.
BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma
Singal, Amit G., Agopian, Vatche G, Dawson, Laura A., El-Khoueiry, Anthony, Finn, Richard S, Halazun, Karim, Kelley, Robin Katie, Kim, Edward , Kulik, Laura, Mehta, Neil, Meyer, Jeffrey , Parikh, Neehar D. , Pillai, Anjana, Salem, Riad, Sapisochin, Gonzalo, Tabrizian, Parissa , Yopp, Adam, Yarchoan, Mark, Parikh, Neehar D , Singal, Amit G. , Agopian, Vatche G. , Dawson, Laura A. , El-Khoueiry, Anthony B. , Finn, Richard S. , Halazun, Karim J. , Heimbach, Julie K. , Kelley, Robin Kate , Kulik, Laura , Mehta, Neil , Mendiratta-Lala, Mishal , Meyer, Jeffrey, Pillai, Anjana , Salem, Riad , Sapisochín, Gonzalo , Yopp, Adam C. , Yarchoan, Mark

Mayo Clinic

Hepatology | August 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001834 | PMID 42565685 Get It

Background : Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality. Optimal treatment decisions are challenging, and existing treatment allocation frameworks may not fully reflect the evolving therapeutic landscape or contemporary clinical practices in North America. Methods : Using a modified Delphi process, a multidisciplinary panel of 20 North American experts in hepatology, medical oncology, surgery, radiology, and radiation oncology developed a consensus-based treatment framework for HCC, termed the BEACON-HCC system. The framework was informed by current evidence and expert opinion through iterative discussion and voting. In a pilot study using 29 real-world patient cases, we assessed concordance between external expert recommendations and BEACON-HCC recommendations and Barcelona Clinic Liver Cancer (BCLC) 2025 treatment recommendations. Results : The BEACON-HCC treatment allocation framework diverges from prior frameworks by incorporating nuanced clinical features such as degree of intrahepatic tumor burden and vascular invasion, and adverse tumor prognostic markers, to align treatment allocation with tumor biology and therapeutic potential. Key innovations include the incorporation of emerging modalities such as external beam radiation therapy (EBRT), transarterial radioembolization (TARE), and systemic-locoregional combination therapies. In the pilot exercise, expert treatment decisions showed 96.6% concordance with BEACON-HCC recommendations and 72.4% concordance with BCLC recommendations. Conclusions : BEACON-HCC is a consensus-based framework for treatment allocation that incorporates the expanding range of therapeutic options available to patients in the North American HCC population. Expert treatment decisions showed a high concordance with the BEACON-HCC system; further validation using empiric clinical data is planned through the HCC-Live Consortium.
Pediatric sarcomas: challenges and opportunities
Gao, Yuan, Bailey, Kelly M. , Blackman, Samuel C. , Bushweller, John H. , Chong, Shasha , DeHond, Kevin, Grembecka, Jolanta , Hatley, Mark E. , Kadoch, Cigall , Koehler, Angela N. , Linardic, Corinne M. , Renna, Phil, Stewart, Elizabeth A., Stillman, Bruce , Sweet-Cordero, E. Alejandro, Reu, Frederic J , Stillman, Bruce , Stegmaier, Kimberly , Vakoc, Christopher R , Guenther, Lillian M , Reu, Frederic J. , Rivera, Miguel N. , Stewart, Elizabeth A. , Sweet-Cordero, Alejandro

Mayo Clinic

Genes & Development | August 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/gad.353549.125 | PMID 42552078 Get It

Pediatric sarcomas are a heterogeneous group of rare mesodermal malignancies. These cancers, which affect children from infancy through adolescence and young adulthood, are in general challenging to treat with currently available therapies. Biologically, many are characterized by quiet genomes, fusion oncoproteins, immune “cold” microenvironments, and vast epigenetic deregulation that contributes to diverse and complex mechanistic drivers. Multifaceted advancements in research strategies, including high-throughput screening, new model systems, surfaceome profiling, and study of oncogenic fusion condensates have led to new opportunities for understanding the biology of pediatric sarcomas. To continue to make progress for these difficult to treat cancers, it will be critical to continue to improve access to bioinformatic data, approach patient care using innovative clinical trial frameworks, and foster interdisciplinary partnerships among medicinal chemists, scientists, clinicians, advocates, and industry partners.
Multicentre randomised comparative effectiveness trial of cleavage-stage versus blastocyst-stage embryo transfer in patients with few embryos (PRECISE): implementation of a study protocol in reproductive medicine
Neuhausser, Werner , Vaughan, Denis A. , Sakkas, Denny, Anchan, Raymond M. , Hornstein, Mark D., Reeder, Harrison T, Barnhart, Kurt T, Cedars, Marcelle I. , Halıcıgil, Cihan , Beck, Michelle, Marsh, Erica E. , Gracia, Clarisa R. , Rosenwaks, Zev, Rabideau, Dustin J. , Trial, Stakeholder Advisory Group and Study Investigators of the PRECISE, Trial, Data and Safety Monitoring Board and Study Investigators of the PRECISE, Neuhausser, Werner M , Sakkas, Denny , Penzias, Alan S. , Reeder, Harrison Thomas , Barnhart, Kurt T. , Stewart, Elizabeth A. , Taylor, Hugh S. , Hacker, Michele R. , Rosenwaks, Zev, Williams, Zev

Mayo Clinic

BMJ Open | August 4, 2026 | Volume: 16 | Issue: 8 | Pages: e107903

10.1136/bmjopen-2025-107903 | PMID 42552004 Get It

Background With improvements in in vitro culture techniques, there has been a steady shift in practice to transfer in vitro fertilisation (IVF) embryos at the blastocyst-stage to increase pregnancy rates per embryo transfer (ET) and reduce the risk of multiple pregnancy. In patients with fewer embryos (≤5 zygotes), fresh cleavage-stage ET is still commonly performed to reduce the risk of cycle cancellation if no embryo survives to the blastocyst-stage in vitro. However, evidence for improved outcomes with cleavage-stage embryo transfer in this subgroup of patients is lacking. We will compare blastocyst-stage to cleavage-stage ET with regard to cumulative live birth rates (CLBR) per oocyte retrieval and other patient-centred cycle outcomes in patients with ≤5 zygotes. Methods and analysis Multicentre, randomised pragmatic comparative effectiveness trial with superiority design comparing blastocyst-stage to cleavage-stage ET in patients with ≤5 zygotes. This trial will enrol and randomise 1126 women aged 18–44 undergoing IVF to either fresh cleavage-stage or blastocyst-stage ET at eleven IVF centres. Surplus embryos will be vitrified at the blastocyst-stage. The primary outcome is the CLBR per oocyte retrieval. Secondary outcomes include: multiple pregnancy, pregnancy loss <20 weeks and cycle cancellation. Exploratory outcomes include: live birth per fresh ET, ectopic pregnancy, time to pregnancy, stillbirth, preterm birth, financial burden, patient distress and facilitators and barriers for patient involvement and implementation. All primary analyses will be conducted according to the intent-to-treat principle. We also will report per-protocol analyses as a sensitivity analysis. A multidisciplinary stakeholder team, including a 5-patient stakeholder panel, will participate in study design, conduct and oversight. Ethics and dissemination The Institutional Review Board at Beth Israel Deaconess Medical Center (BIDMC) provides central regulatory oversight. Results will inform timing of embryo transfer in patients with ≤5 zygotes and will be disseminated through academic publications, meeting presentations and communications to advocacy groups and patient participants. Trial registration number NCT06746129 .
Sedentary Behavior and Physical Activity in Individuals With Bipolar Disorder: An Evidence Synthesis and Position Statement From the ISBD Nutrition and Exercise Task Force (NExT)
Lafer, Beny , Neves, Lucas Melo , Vancampfort, Davy , Stubbs, Brendon, Gonzalez‐Pinto, Ana, Nierenberg, Andrew A. , Goldstein, Benjamin I. , Koning, Elena , Gomes, Fabiano A., Saraf, Gayatri , Sylvia, Louisa G. , Solmi, Marco, Frye, Mark A. , Berk, Michael , Mansur, Rodrigo B., Marx, Wolfgang, Schuch, Felipe, Brietzke, Elisa , Stubbs, Brendon , Neves, Lucas M , Nierenberg, Andrew A , Olagunju, Andrew T , Goldstein, Benjamin I , Vieta, E , Koning, Elena , Fiedorowicz, Jess G , Yatham, Lakshmi N , Sylvia, Louisa , Vinberg, Maj , Gardea-Resendez, Manuel , Frye, Mark , Berk, Michael , Alsuwaidan, Mohammad , Milev, Roumen , Rosenbaum, Simon , Van Rheenen, Tamsyn , Balanzá-Martínez, Vicent , Solmi, Marco , Gonzalez-Pinto, Ana, Olagunju, Andrew T , Vieta, Eduard , Fiedorowicz, Jess G. , Yatham, Lakshmi N. , Gardea‐Resendez, Manuel , Solmi, Marco , Mansur, Rodrigo Barbachan , Marx, Wolfgang , Schuch, Felipe Barreto

Mayo Clinic

Bipolar Disorders | August 3, 2026 | Volume: 28 | Issue: 5 | Pages: No page available

10.1111/bdi.70164 | PMID 42545207 Get It

ABSTRACT Background Higher time in sedentary behavior and insufficient physical activity are very common in bipolar disorder (BD). Whereas physical activity and exercise offer significant benefits across mental health, brain health, and heart health in BD. The International Society for Bipolar Disorders Nutrition and Exercise Task Force (NExT) synthesized evidence to evaluate the impacts of sedentary behavior, physical activity, and exercise on illness course, physical health, and treatment outcomes. Methods A best‐evidence synthesis was conducted using a question‐and‐answer format. We searched PsycINFO, SPORTDiscus, Embase, PubMed, and Web of Science from inception to March 1st, 2026, supplemented by reference lists and existing guidelines. Search terms included combinations of physical activity, exercise, sedentary behavior, and bipolar disorder‐related terms. Results Observational studies show that individuals with BD exhibit significantly higher sedentary behavior and lower physical activity compared to the general population, with notable discrepancies between self‐reported and objective measurements. Evidence on physical activity's protective role against BD onset is mixed, with some prospective and Mendelian randomization studies suggesting reduced risk, while others report bidirectional or null associations. Preliminary findings from clinical trials indicate that exercise improves overall functioning, reduces mood episode frequency and hospitalizations, and alleviates depressive symptoms, with one pilot study showing an 82% antidepressant response rate. Exercise also shows potential to reduce anxiety and improve sleep, though robust data are limited. Conclusions Despite limited high‐quality evidence, physical activity and exercise demonstrate promising physical and mental health benefits for individuals with BD. Future research should prioritize multicenter randomized controlled trials, enhanced assessment tools, and accessible, tailored programs to integrate physical activity into routine BD management.
Malignant B-cell States Orchestrate Spatially Organized Immune Ecosystems in B-cell Lymphomas
Mondello, Patrizia , Sadekova, Alisa , fede, ksenia, Dasari, Surendra , Au, Wesley , Kriukov, Kirill , Meerson, Mark, Novak, Joseph, Yang, Zhi-Zhang , Gysbers, Brianna J. , Villasboas, Jose, Wiebe, Daniil S. , Shvyrkova, Anastasiia, Margaryan, Sargis, Nesmelov, Alexander, Sarachakov, Aleksander, Petrosyants, Arman, Bagaev, Alexander , Novak, Anne J. , Casulo, Carla, Hsi, Eric, Fowler, Nathan, King, Rebecca, Singh, Harinder, Armand, Philippe, Pasqualucci, Laura, Ansell, Stephen M. , Binder, Moritz , Yang, Zhi-Zhang , Gysbers, Brianna J , Postovalova, Ekaterina , Wiebe, Daniil , Kotlov, Nikita , Wang, Yucai , Novak, Anne J , Habermann, Thomas , Maurer, Matthew , Cerhan, James R , Shlomchik, Mark , Ansell, Stephen M , Mondello, Patrizia , Dasari, Surendra , Au, Wesley, Binder, Moritz , Meerson, Mark , Novak, Joseph P. , Villasboas, José C. , Guzman, Emmanuel Contreras , Nesmelov, Alexander, Wang, Yucai , Habermann, Thomas M. , Hsi, Eric D. , Maurer, Matthew J. , Cerhan, James R. , Singh, Harinder, Armand, P., Pasqualucci, Laura , Burack, Richard

Mayo Clinic

No container title available | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10435263/v1 | PMID 42620132 Get It

Abstract Germinal center (GC)-derived lymphomas arise within a specialized immune ecosystem, yet whether malignant cells direct its remodeling remains unclear. Integrating genomic, transcriptomic, spatial, and functional analyses across follicular lymphoma and diffuse large B-cell lymphoma, we define a developmental framework linking malignant B-cell differentiation state to tumor microenvironment (TME) organization. Rather than segregating by histology, lymphomas align along a shared differentiation continuum in which proliferative dark zone (DZ) states associate with immune-depleted TMEs, whereas post-GC/memory B-cell (MBC) states drive inflamed but immunosuppressed TMEs. Spatial profiling reveals collapse of GC architecture and emergence of suppressive myeloid niches along this trajectory. Single-cell lineage reconstruction uncovers a DZ-to-MBC developmental axis underlying lymphoma evolution. Genetic reprogramming in vivo demonstrates that malignant differentiation state is sufficient to instruct TME remodeling. Collectively, these findings establish malignant differentiation state as a causal determinant of immune architecture across GC-derived lymphomas and identify lineage-directed immune reprogramming as a potential therapeutic strategy.